Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine Carcinoma
Status:
Unknown status
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
Currently, there is no standard second line treatment for patients with neuroendocrine
carcinoma. SOX regimen has shown promising in previous study. The study was designed to
confirm thet SOX regimen can be used as a second-line regimen for patients with advanced or
metastatic neuroendocrine carcinoma who have progressed after first-line chemotherapy with
platinum based regimen.